Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93401ArticlesСтатьиResearch ArticleFarmakoterapiya revmatoidnogo artrita u beremennykh zhenshchinФармакотерапия ревматоидного артрита у беременных женщинUshkalovaE. AУшкаловаЕ. А

Кафедра общей и клинической фармакологии

RomanovaO. LРомановаО. Л

Кафедра общей и клинической фармакологии

IllarionovaT. SИлларионоваТ. С

Кафедра общей и клинической фармакологии

ГОУ ВПО РУДН Минздравсоцразвития РФ, Москва15062011136VOL 13, NO6 (2011)ТОМ 13, №6 (2011)586128122021Copyright ©; 2011, Consilium MedicumCopyright ©; 2011, ООО "Консилиум Медикум"2011Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93401

У женщин (преимущественно репродуктивного возраста) ревматоидный артрит (РА) наблюдается в 2–3 раза чаще, чем у мужчин. Заболевание невлияет на фертильность, однако может ухудшать течение и исходы беременности [1]. Частота преждевременных родов у женщин, страдающих РА, достигает 25% случаев по сравнению с 10% у здоровых женщин, а средний вес детей, в том числе доношенных, достоверно ниже, чем у женщин без данного заболевания [2]. Кроме того, у беременных пациенток с РА выше риск развития преэклампсии и чаще встречаются показания к кесареву сечению [3]. Неблагоприятные исходы беременности коррелируют с активностью воспалительного процесса в суставах, поэтому рациональное лечение РА в период гестации приносит пользу не только матери, но и ребенку. Однако выбор лекарственных средств (ЛС) в период гестации осложняется тем, что многие из препаратов, применяемых для лечения РА, обладают эмбриотоксическим и тератогенным действием, что требует заблаговременного планирования беременности и тщательной подготовки к ней.Возможности фармакотерапии РА у беременных женщин достаточно широки [7]. Для облегчения боли можно использовать парацетамол, нестероидные противовоспалительные препараты (НПВП) или препараты, модифицирующие заболевание.

Ostensen M, Fuhrer L, Mathieu R et al. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 2004; 63: 1212–7.Bowden A.P., Barrett J.H., Fallow W et al. Women with inflammatory polyarthritis have babies of lower birth weight. J Rheumatol 2001; 28: 355–9.Chakravarty E.F., Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 899–907.Mitchell K, Kaul M, Clowse M.E.B. The management of rheumatic diseases in pregnancy Scandinavian Journal of Rheumatology 2010; 39 (2): 99–108;Janssen N.M., Genta M.S. The effects of immunosuppressive and anti - inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000; 160: 610–9.Ostensen M. Förger F. Management of RA medications in pregnant patients. Nature Reviews Rheumatology 2009; 5: 382–90.De Man Y.A., Dolhain R.J., Van de Geijn F.E. et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008; 59 (9): 1241–8.Lortscher D.N., Bransington R.D. Rheumatoid arthritis: treatment of newly diagnosed disease. Available at: http://www.consultantlive.com/ showArticle.jhtml?articleId5206503916 2008Bermas B.L. Use of immunosuppressive drugs in pregnancy and lactation. 2008. Available at http://www.utdol.com. lrc1.usuhs.edu/ utd/content/topic.do?topicKey5tx_rheum/9876Piggott K.D., Sorbello A, Riddle E et al.Congenital cardiac defects: a possible association of aminopterin syndrome and in utero methotrexate exposure? Pediatr Cardiol 2011; 32 (4): 518–20.No authors listed. High - dose methotrexate during pregnancy: risk of malformations. Prescribe Int 2010; 19 (109): 212–3.Vroom F, de Walle H.E., van de Laar M.A. et al. Disease - modifying antirheumatic drugs in pregnancy: current status and implications for the future. Drug Saf 2006; 29 (10): 845–63.Gromnica-Ihle E, Krüger K. Use of methotrexate in young patients with respect to the reproductive system. Clin Exp Rheumatol 2010; 28 (Suppl. 61): 580–4.Visser K, Katchamart W, Loza E et al. Multinational evidence - based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative Ann Rheum Dis 2009; 68 (7): 1086–93.Chambers C, Johnson D, Robinson L et al. Birth Outcomes in Women Who Have Taken Leflunomide During Pregnancy. Arthritis & rheumatism May 2010; 62 (5): 1494–503.Sifontis N.M., Coscia L.A., Constantinescu S et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82: 1698–702.Orencia® (abatacept; lyophilized powder for intravenous infusion) package insert. Bristol – Myers Squibb, 2008.Levy S et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2008; 44: 428–30.Mitchel, Clowse M.E.B. The use of anti - TNFα medications for rheumatologic disease in pregnancy. Int J Women Health 2010; 2: 199–209.Vasiliu V, Lazarescu R, Popescu A, Grigoriu E et al. Lupus erythematosus (L.E.) and pregnancy and the puerperium, in Romanian. Med Interna (Bucur) 1969; 21: 99–104.Caprilli R, Gassull M.A., Escher J.C. et al. European evidence - based consensus on the diagnosis and management of Crohn\'s disease: special situations. Gut 2006; 55 (Suppl. 1): 136–58.Etminan M, Sadatsafavi M, Jafari S et al. Acetaminophen use and the risk of asthma in children and adults: a systematic review and metaanalysis. Chest 2009; 136 (5): 1316–23.Nielsen G.L., Sorensen H.T., Larsen H et al. Risk of adverse birth outcome and miscarriage in pregnant users of non - steroidal anti - inflammatory drugs: population based observational study and case - control study. BMJ 2001; 322: 266–70.Li D.K., Liu L, Odouli R. Exposure to non - steroidal anti - inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study BMJ 2003; 327 (7411): 368.Bermas B.L. Management of Rheumatologic Disorders During Pregnancy. Int J Clin Rheumatol 2010.Cowchock F.S. et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low - dose heparin treatment. Am J Obstet Gynecol 1992; 166 (5): 1318–23.Ostensen M, von Esebeck M, Villiger P.M. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 2007; 34 (6): 1266–9.Carmichael S L et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197: 585e1–e7.Sperber K, Hom C, Chao C.P., Shapiro D et al. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 2009; p. 7–9.Costedoat-Chalumeau N et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty - three cases compared with a control group. Arthritis Rheum 2003; 48: 3207–11.Klinger G et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001; 358: 813–4.Moskovitz D.N. et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel - disease patients. Am J Gastroenterol 2004; 99: 656–61.Friedman J.M. Teratogen update: azathioprine and 6 - mercaptopurine. Teratol 2002; 65: 240–61.Goldstein L H et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79: 696–701.Norgard B, Pedersen L, Christensen L.A. & Sörensen H.T. Therapeutic drug use in women with Crohn\'s disease and birth outcomes: A Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406–13.Armenti V.T. et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. In: Clinical Transplants (Eds J.M.Cecka & P.I.Terasaki) 2004; 103–114 (UCLA, Los Angeles, 2004).Bar Oz B, Hackman R, Einarson T & Koren G. Pregnancy outcome after CsA therapy during pregnancy: a meta - analysis. Transplantation 2001; 71: 1051–5.Shaheen F.A.M., AI-Sulaiman M.H. & AI-Khader A.A. Long - term nephrotoxicity after exposure to CsA in utero. Transplantation 1993; 56: 224–5.